Inari Medical, Inc. (NARI)

Market Cap	2.23B
Revenue (ttm)	493.63M
Net Income (ttm)	-1.64M
Shares Out	57.96M
EPS (ttm)	-0.03
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	769,216
Open	38.02
Previous Close	38.07
Day's Range	37.97 - 38.97
52-Week Range	36.73 - 71.85
Beta	0.85
Analysts	Buy
Price Target	69.33 (+80.45%)
Earnings Date	Apr 30, 2024

About NARI

Inari Medical, Inc. builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embol...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: May 22, 2020
• Employees: 1,300
• Stock Exchange: NASDAQ
• Ticker Symbol: NARI

Financial Performance

In 2023, Inari Medical's revenue was $493.63 million, an increase of 28.73% compared to the previous year's $383.47 million. Losses were -$1.64 million, -94.41% less than in 2022.

Analyst Forecast

According to 6 analysts, the average rating for NARI stock is "Buy." The 12-month stock price forecast is $69.33, which is an increase of 80.45% from the latest price.

Price Target

$69.33

(80.45% upside)

Analyst Consensus: Buy